Association of Proximal Tubular Secretory Clearance with Long-Term Decline in Cognitive Function

被引:7
作者
Lidgard, Benjamin [1 ,17 ]
Bansal, Nisha [1 ]
Zelnick, Leila R. [1 ]
Hoofnagle, Andrew [1 ]
Chen, Jing [2 ]
Colaizzo, Derek [3 ]
Dobre, Mirela [4 ]
Mills, Katherine T. [2 ]
Porter, Anna C. [5 ]
Rosas, Sylvia E. [6 ,7 ]
Sarnak, Mark J. [8 ]
Seliger, Stephen [9 ]
Sondheimer, James [10 ]
Tamura, Manjula Kurella [11 ,12 ]
Yaffe, Kristine [13 ,14 ,15 ,16 ]
Kestenbaum, Bryan [1 ]
机构
[1] Univ Washington, Dept Lab Med & Pathol, Seattle, WA USA
[2] Tulane Univ, Dept Med, New Orleans, LA USA
[3] Univ Penn, Philadelphia, PA USA
[4] Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Cleveland, OH USA
[5] Univ Illinois, Dept Med, Sect Nephrol, Chicago, IL USA
[6] Joslin Diabet Ctr, Kidney & Hypertens Unit, Boston, MA USA
[7] Harvard Med Sch, Boston, MA USA
[8] Tufts Med Ctr, Dept Med, Boston, MA USA
[9] Univ Maryland, Dept Med, Sch Med, Baltimore, MD USA
[10] Wayne State Univ, Dept Med, Div Nephrol, Detroit, MI USA
[11] Stanford Univ, Dept Med, Palo Alto, CA USA
[12] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA
[13] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA USA
[14] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA USA
[15] Univ Calif San Francisco, Sch Med, Dept Epidemiol, San Francisco, CA USA
[16] Univ Calif San Francisco, Sch Med, Dept Biostat, San Francisco, CA USA
[17] Univ Washington, Kidney Res Inst, 908 Jefferson St,3rdfloor, Seattle, WA 98104 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 07期
基金
美国国家卫生研究院;
关键词
chronic kidney disease; kidney tubule; uremia; cognition; CHRONIC KIDNEY-DISEASE; ORGANIC ANION TRANSPORTERS; INDOXYL SULFATE; RISK-FACTORS; KYNURENINE PATHWAY; UREMIC TOXINS; IMPAIRMENT; INVOLVEMENT; METABOLITES; CREATININE;
D O I
10.1681/ASN.2021111435
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background People with chronic kidney disease (CKD) are at high risk for cognitive impairment and progressive cognitive decline. Retention of protein-bound organic solutes that are normally removed by tubular secretion is hypothesized to contribute to cognitive impairment in CKD. Methods We followed 2362 participants who were initially free of cognitive impairment and stroke in the prospective Chronic Renal Insufficiency Cohort (CRIC) Study. We estimated tubular secretory clearance by the 24-hour kidney clearances of eight endogenous solutes that are primarily eliminated by tubular secretion. CRIC study investigators assessed participants' cognitive function annually using the Modified Mini-Mental State (3MS) Examination. Cognitive decline was defined as a sustained decrease of more than five points in the 3MS score from baseline. Using Cox regression models adjusted for potential confounders, we analyzed associations between secretory solute clearances, serum solute concentrations, and cognitive decline. Results The median number of follow-up 3MS examinations was six per participant. There were 247 incident cognitive decline events over a median of 9.1 years of follow-up. Lower kidney clearances of five of the eight secretory solutes (cinnamoylglycine, isovalerylglycine, kynurenic acid, pyridoxic acid, and tiglylglycine) were associated with cognitive decline after adjustment for baseline eGFR, proteinuria, and other confounding variables. Effect sizes ranged from a 17% to a 34% higher risk of cognitive decline per 50% lower clearance. In contrast, serum concentrations of the solutes were not associated with cognitive decline. Conclusions Lower kidney clearances of secreted solutes are associated with incident global cognitive decline in a prospective study of CKD, independent of eGFR. Further work is needed to determine the domains of cognition most affected by decreased secretory clearance and the mechanisms of these associations.
引用
收藏
页码:1391 / 1401
页数:11
相关论文
共 69 条
[31]   Protein-bound uremic toxins are associated with cognitive function among patients undergoing maintenance hemodialysis [J].
Lin, Yi-Ting ;
Wu, Ping-Hsun ;
Liang, Shih-Shin ;
Mubanga, Mwenya ;
Yang, Yuan-Han ;
Hsu, Ya-Ling ;
Kuo, Mei-Chuan ;
Hwang, Shang-Jyh ;
Kuo, Po-Lin .
SCIENTIFIC REPORTS, 2019, 9 (1)
[32]   Kidney-brain crosstalk in the acute and chronic setting [J].
Lu, Renhua ;
Kiernan, Matthew C. ;
Murray, Anne ;
Rosner, Mitchell H. ;
Ronco, Caudio .
NATURE REVIEWS NEPHROLOGY, 2015, 11 (12) :707-719
[33]   Neuropsychiatric complications of chronic kidney disease [J].
McQuillan, Rory ;
Jassal, Sarbjit V. .
NATURE REVIEWS NEPHROLOGY, 2010, 6 (08) :471-479
[34]   Effects of Chronic Renal Failure on Kidney Drug Transporters and Cytochrome P450 in Rats [J].
Naud, Judith ;
Michaud, Josee ;
Beauchemin, Stephanie ;
Hebert, Marie-Josee ;
Roger, Michel ;
Lefrancois, Stephane ;
Leblond, Francois A. ;
Pichette, Vincent .
DRUG METABOLISM AND DISPOSITION, 2011, 39 (08) :1363-1369
[35]  
Nielsen Jonas Ellegaard, 2021, Metabol Open, V12, P100125, DOI 10.1016/j.metop.2021.100125
[36]   Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain [J].
Ohtsuki, S ;
Asaba, H ;
Takanaga, H ;
Deguchi, T ;
Hosoya, K ;
Otagiri, M ;
Terasaki, T .
JOURNAL OF NEUROCHEMISTRY, 2002, 83 (01) :57-66
[37]  
Pawlak D, 2003, J PHYSIOL PHARMACOL, V54, P175
[38]   Accumulation of toxic products degradation of kynurenine in hemodialyzed patients [J].
Pawlak D. ;
Pawlak K. ;
Malyszko J. ;
Mysliwiec M. ;
Buczko W. .
International Urology and Nephrology, 2001, 33 (2) :399-404
[39]   Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure [J].
Pawlak, D ;
Tankiewicz, A ;
Mysliwiec, P ;
Buczko, W .
NEPHRON, 2002, 90 (03) :328-335
[40]   Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: Implications for schizophrenia [J].
Pershing, Michelle L. ;
Bortz, David M. ;
Pocivavsek, Ana ;
Fredericks, Peter J. ;
Jorgensen, Christinna V. ;
Vunck, Sarah A. ;
Leuner, Benedetta ;
Schwarcz, Robert ;
Bruno, John P. .
NEUROPHARMACOLOGY, 2015, 90 :33-41